Hartman Institute for Therapeutic Organ Regeneration

Redox modification of nuclear actin by MICAL-2 regulates SRF signaling.

TitleRedox modification of nuclear actin by MICAL-2 regulates SRF signaling.
Publication TypeJournal Article
Year of Publication2014
AuthorsLundquist MR, Storaska AJ, Liu T-C, Larsen SD, Evans T, Neubig RR, Jaffrey SR
JournalCell
Volume156
Issue3
Pagination563-76
Date Published2014 Jan 30
ISSN1097-4172
KeywordsActins, Amino Acid Sequence, Anilides, Animals, Benzamides, Cell Line, Cell Nucleus, Cells, Cultured, DNA-Binding Proteins, Gene Knockdown Techniques, Humans, Mice, Microfilament Proteins, Mixed Function Oxygenases, Molecular Sequence Data, Nerve Growth Factor, Neurites, Oncogene Proteins, Fusion, Oxidation-Reduction, Oxidoreductases, Rats, Sequence Alignment, Serum Response Factor, Signal Transduction, Trans-Activators, Transcription, Genetic, Zebrafish
Abstract

<p>The serum response factor (SRF) binds to coactivators, such as myocardin-related transcription factor-A (MRTF-A), and mediates gene transcription elicited by diverse signaling pathways. SRF/MRTF-A-dependent gene transcription is activated when nuclear MRTF-A levels increase, enabling the formation of transcriptionally active SRF/MRTF-A complexes. The level of nuclear MRTF-A is regulated by nuclear G-actin, which binds to MRTF-A and promotes its nuclear export. However, pathways that regulate nuclear actin levels are poorly understood. Here, we show that MICAL-2, an atypical actin-regulatory protein, mediates SRF/MRTF-A-dependent gene transcription elicited by nerve growth factor and serum. MICAL-2 induces redox-dependent depolymerization of nuclear actin, which decreases nuclear G-actin and increases MRTF-A in the nucleus. Furthermore, we show that MICAL-2 is a target of CCG-1423, a small molecule inhibitor of SRF/MRTF-A-dependent transcription that exhibits efficacy in various preclinical disease models. These data identify redox modification of nuclear actin as a regulatory switch that mediates SRF/MRTF-A-dependent gene transcription.</p>

DOI10.1016/j.cell.2013.12.035
Alternate JournalCell
PubMed ID24440334
PubMed Central IDPMC4384661
Grant ListF32AT4340 / AT / NCCIH NIH HHS / United States
NS56306 / NS / NINDS NIH HHS / United States
R01 NS056306 / NS / NINDS NIH HHS / United States
R01 HL111400 / HL / NHLBI NIH HHS / United States
HL111400 / HL / NHLBI NIH HHS / United States
F31 AT004340 / AT / NCCIH NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065